Pay attention to comment made twice in the "pathetic news release". 

This is far from done snd the degree of the confusion speaks to the value of the shares

never once was the interim data efficacy disclosed. Only an insider financing on the back of the 600 / 650 patient revision

I would read the twice used "with this sample size" in the NR